Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 344

1.

A population-based study of cardiovascular disease mortality risk in US cancer patients.

Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, Kelly SP, Zaorsky NG.

Eur Heart J. 2019 Nov 25. pii: ehz766. doi: 10.1093/eurheartj/ehz766. [Epub ahead of print]

PMID:
31761945
2.

Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup.

Venkatramani V, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Soodana-Prakash N, Becerra MF, Swain S, Kendrick K, Smith JA Jr, Thompson IM, Parekh DJ.

J Urol. 2019 Sep 24:101097JU0000000000000565. doi: 10.1097/JU.0000000000000565. [Epub ahead of print]

PMID:
31549935
3.

Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA.

J Urol. 2019 Nov;202(5):920-926. doi: 10.1097/JU.0000000000000355. Epub 2019 Oct 9.

PMID:
31120373
4.

Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients.

Psutka SP, Barocas DA, Catto JWF, Gore JL, Lee CT, Morgan TM, Master VA, Necchi A, Rouprêt M, Boorjian SA.

Eur Urol Oncol. 2018 Sep;1(4):292-304. doi: 10.1016/j.euo.2018.05.010. Epub 2018 Jun 19. Review.

PMID:
31100250
5.

Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy.

McAlpine K, Lavallée LT, Stacey D, Moodley P, Cagiannos I, Morash C, Black PC, Kulkarni GS, Shayegan B, Kassouf W, Siemens R, So A, Leveridge MJ, Boorjian SA, Daneshmand S, Smith AB, Power N, Izawa J, Drachenberg DE, Fairey A, Rendon RA, Breau RH.

J Urol. 2019 Nov;202(5):1001-1007. doi: 10.1097/JU.0000000000000341. Epub 2019 Oct 9.

PMID:
31099720
6.

Intracorporeal orthotopic neobladder formation: Why not to do it?

Faraj KS, Abdul-Muhsin HM, Navaratnam AK, Rose KM, Castle EP.

Arch Esp Urol. 2019 Apr;72(3):318-325. Review.

PMID:
30945659
7.

The Microbiome and Genitourinary Cancer: A Collaborative Review.

Markowski MC, Boorjian SA, Burton JP, Hahn NM, Ingersoll MA, Maleki Vareki S, Pal SK, Sfanos KS.

Eur Urol. 2019 Apr;75(4):637-646. doi: 10.1016/j.eururo.2018.12.043. Epub 2019 Jan 15. Review.

PMID:
30655087
8.

Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis.

Al-Husseini MJ, Kunbaz A, Saad AM, Santos JV, Salahia S, Iqbal M, Alahdab F.

BMC Cancer. 2019 Jan 10;19(1):46. doi: 10.1186/s12885-019-5267-3.

9.

Prognostic Factors and a Survival Score in Patients Irradiated for Metastatic Epidural Spinal Cord Compression from Urothelial Carcinoma Cancer of the Bladder.

Rades D, Sondermann L, Motisi L, Janssen S, Cacicedo J, Schild SE.

Anticancer Res. 2018 Dec;38(12):6841-6846. doi: 10.21873/anticanres.13058.

PMID:
30504399
10.

Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation.

Mitra AP, Fairey AS, Skinner EC, Boorjian SA, Frank I, Schoenberg MP, Bivalacqua TJ, Hyndman ME, Reese AC, Steinberg GD, Large MC, Hulsbergen-van de Kaa CA, Bruins HM, Daneshmand S.

Urol Oncol. 2019 Jan;37(1):48-56. doi: 10.1016/j.urolonc.2018.10.013. Epub 2018 Nov 13.

PMID:
30446450
11.

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM.

Lancet Oncol. 2018 Nov;19(11):1504-1515. doi: 10.1016/S1470-2045(18)30528-X. Epub 2018 Oct 10. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

12.

Updates and novel treatments in urothelial carcinoma.

Hanna KS.

J Oncol Pharm Pract. 2019 Apr;25(3):648-656. doi: 10.1177/1078155218805141. Epub 2018 Oct 10. Review.

PMID:
30304985
13.

Update of the ICUD-SIU International Consultation on Bladder Cancer 2018: urinary diversion.

Faba OR, Tyson MD, Artibani W, Bochner BH, Burkhard F, Gilbert SM, Kälble T, Madersbacher S, Seiler R, Skinner EC, Thalmann G, Thüroff J, Wiklund P, Hautmann R, Palou J.

World J Urol. 2019 Jan;37(1):85-93. doi: 10.1007/s00345-018-2484-3. Epub 2018 Sep 20. Review.

PMID:
30238399
14.

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.

Soria F, Pisano F, Gontero P, Palou J, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes JA, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Sylvester R.

World J Urol. 2018 Nov;36(11):1775-1781. doi: 10.1007/s00345-018-2450-0. Epub 2018 Aug 31.

PMID:
30171454
15.

Behavior of blood plasma glycan features in bladder cancer.

Ferdosi S, Ho TH, Castle EP, Stanton ML, Borges CR.

PLoS One. 2018 Jul 24;13(7):e0201208. doi: 10.1371/journal.pone.0201208. eCollection 2018.

16.

Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer.

Matsuo K, Machida H, Mariani A, Mandelbaum RS, Glaser GE, Gostout BS, Roman LD, Wright JD.

J Gynecol Oncol. 2018 Sep;29(5):e69. doi: 10.3802/jgo.2018.29.e69. Epub 2018 May 4.

17.

Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.

Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM.

Lancet. 2018 Jun 23;391(10139):2525-2536. doi: 10.1016/S0140-6736(18)30996-6.

PMID:
29976469
18.

The Association of Aspirin Use with Survival Following Radical Cystectomy.

Lyon TD, Frank I, Shah PH, Tarrell R, Cheville JC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA.

J Urol. 2018 Nov;200(5):1014-1021. doi: 10.1016/j.juro.2018.05.119. Epub 2018 May 30.

PMID:
29857079
19.

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.

Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, Den RB, Jeffrey Karnes R, Klein E, Hoskin PJ, Freedland SJ, Lamb AD, Neal DE, Buffa FM, Bristow RG, Boutros PC, Davicioni E, Choudhury A, West CML.

EBioMedicine. 2018 May;31:182-189. doi: 10.1016/j.ebiom.2018.04.019. Epub 2018 Apr 23.

20.

ACR Appropriateness Criteria® Pretreatment Staging of Muscle-Invasive Bladder Cancer.

Expert Panel on Urologic Imaging:, van der Pol CB, Sahni VA, Eberhardt SC, Oto A, Akin O, Alexander LF, Allen BC, Coakley FV, Froemming AT, Fulgham PF, Hosseinzadeh K, Maranchie JK, Mody RN, Schieda N, Schuster DM, Venkatesan AM, Wang CL, Lockhart ME.

J Am Coll Radiol. 2018 May;15(5S):S150-S159. doi: 10.1016/j.jacr.2018.03.020.

PMID:
29724418

Supplemental Content

Loading ...
Support Center